A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

Completed · Phase 1

Conditions studied: Non-small Cell Lung Cancer

In brief

The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and digoxin in the body when it is given with and without another medicine called calderasib. Researchers are testing if digoxin and midazolam levels in the body are different when digoxin and midazolam are given with or without calderasib.

Key facts

Study ID

NCT06575933

Run by

Merck Sharp & Dohme LLC

People needed

28

Starts

2024-09-03

Expected to finish

2024-10-28

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Is medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vitals signs, and electrocardiograms (ECGs)
• Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• Has a medical history that may confound the results of the study or poses an additional risk to the participant in the study
• Has a history or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds

Where it is running

• Celerion ( Site 0001) — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.